Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMedDx Steps Into Public Sphere: Director Details Diagnostics Priorities

This article was originally published in The Gray Sheet

Executive Summary

The recently established diagnostics arm of AdvaMed had what its executive director called a coming out party last week.

You may also be interested in...



Medicare Dx Payment System Will Be Market-Based, More Transparent Under New Law

Although the changes ultimately may lead to payment reductions, both test kits makers and laboratories applaud the new provisions. Reimbursement will better reflect the value that lab tests bring to the health care system, they say.

Medicare Dx Payment System Will Be Market-Based, More Transparent Under New Law

A new law makes vast changes to how clinical laboratory tests will be reimbursed by Medicare over the long term. Although the changes ultimately may lead to payment reductions, both test kits makers and laboratories applaud the new provisions. Reimbursement will better reflect the value that lab tests bring to the health care system, they say.

News In Brief

Transcatheter valve registry launched. Qiagen cuts costs. FCC grants RF spectrum for Medical Micropower Networks. More industry news.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel